Ribavirin
- Generic Name
- Ribavirin
- Brand Names
- Ibavyr, Rebetol, Virazole
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O5
- CAS Number
- 36791-04-5
- Unique Ingredient Identifier
- 49717AWG6K
- Background
Producing a broad-spectrum activity against several RNA and DNA viruses, Ribavirin is a synthetic guanosine nucleoside and antiviral agent that interferes with the synthesis of viral mRNA. It is primarily indicated for use in treating hepatitis C and viral hemorrhagic fevers. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes...
- Indication
Indicated for the treatment of chronic Hepatitis C virus (HCV) infection in combination with other antiviral agents with the intent to cure or achieve a sustained virologic response (SVR). Typically added to improve SVR and reduce relapse rates .
...
- Associated Conditions
- Chronic Hepatitis C Virus (HCV) Infection, Severe Respiratory Syncytial Virus Infection
- Associated Therapies
- -
Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults
- Conditions
- First Posted Date
- 2005-01-04
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 2
- Registration Number
- NCT00100581
- Locations
- 🇺🇸
Columbia Univ., HIV Prevention and Treatment Medical Ctr., New York, New York, United States
🇺🇸Univ. of Texas Southwestern Med. Ctr., Amelia Court Continuity Clinic, Dallas, Texas, United States
A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C
- Conditions
- First Posted Date
- 2004-11-24
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Human Genome Sciences Inc.
- Target Recruit Count
- 115
- Registration Number
- NCT00097435
- Locations
- 🇺🇸
Mayo Clinic, Phoenix, Arizona, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Mayo Clinic Rochester, Rochester, Minnesota, United States
Omega Interferon Alone or in Combination With Ribavirin in Subjects With Hepatitis C
- Conditions
- First Posted Date
- 2004-11-18
- Last Posted Date
- 2007-08-23
- Lead Sponsor
- Intarcia Therapeutics
- Target Recruit Count
- 90
- Registration Number
- NCT00097045
Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive
- Conditions
- First Posted Date
- 2004-10-04
- Last Posted Date
- 2012-06-22
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 900
- Registration Number
- NCT00093093
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇨🇦Toronto Western Hospital, Toronto, Ontario, Canada
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin
- Conditions
- Interventions
- First Posted Date
- 2004-07-14
- Last Posted Date
- 2016-06-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 57
- Registration Number
- NCT00087568
REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy
- Conditions
- Interventions
- First Posted Date
- 2004-07-14
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 948
- Registration Number
- NCT00087646
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program.
- Conditions
- Interventions
- First Posted Date
- 2004-07-14
- Last Posted Date
- 2016-03-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 48
- Registration Number
- NCT00087594
Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).
- Conditions
- Interventions
- First Posted Date
- 2004-07-14
- Last Posted Date
- 2016-07-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 385
- Registration Number
- NCT00087607
Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation
- Conditions
- First Posted Date
- 2004-04-13
- Last Posted Date
- 2010-04-02
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00014391
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)
- Conditions
- Interventions
- First Posted Date
- 2004-02-25
- Last Posted Date
- 2021-11-08
- Target Recruit Count
- 333
- Registration Number
- NCT00078403
- Locations
- 🇺🇸
Johns Hopkins University CRS, Baltimore, Maryland, United States
🇺🇸University of Pittsburgh CRS, Pittsburgh, Pennsylvania, United States
🇺🇸Massachusetts General Hospital CRS (MGH CRS), Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.